These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 22623328)

  • 21. Methodological challenges for the evaluation of clinical effectiveness in the context of accelerated regulatory approval: an overview.
    Woolacott N; Corbett M; Jones-Diette J; Hodgson R
    J Clin Epidemiol; 2017 Oct; 90():108-118. PubMed ID: 28709997
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses.
    Stang A
    Eur J Epidemiol; 2010 Sep; 25(9):603-5. PubMed ID: 20652370
    [No Abstract]   [Full Text] [Related]  

  • 23. Clinical and economic outcomes--friend or foe?
    Wimo A
    Int Psychogeriatr; 2007 Jun; 19(3):497-507. PubMed ID: 17346367
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Some problems with the investigation of noninferiority in meta-analysis.
    Witte S; Victor N
    Methods Inf Med; 2004; 43(5):470-4. PubMed ID: 15702203
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mega-trials vs. meta-analysis: precision vs. heterogeneity?
    Shrier I; Platt RW; Steele RJ
    Contemp Clin Trials; 2007 May; 28(3):324-8. PubMed ID: 17188025
    [TBL] [Abstract][Full Text] [Related]  

  • 26. On the utility of the Dirichlet distribution for meta-analysis of clinical studies.
    Sankoh AJ; Al-Osh M; Huque MF
    J Biopharm Stat; 1999 May; 9(2):289-306. PubMed ID: 10379695
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Information-theory based surrogate marker evaluation from several randomized clinical trials with continuous true and binary surrogate endpoints.
    Pryseley A; Tilahun A; Alonso A; Molenberghs G
    Clin Trials; 2007; 4(6):587-97. PubMed ID: 18042568
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Meta-analysis: methods, strengths, and weaknesses.
    Buyse M; Piedbois P; Piedbois Y; Carlson RW
    Oncology (Williston Park); 2000 Mar; 14(3):437-43; discussion 444, 447. PubMed ID: 10742969
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Complete cytogenetic response and major molecular response as surrogate outcomes for overall survival in first-line treatment of chronic myelogenous leukemia: a case study for technology appraisal on the basis of surrogate outcomes evidence.
    Oriana C; Martin H; Toby P; Chris C; Ruth G; Claudius R; Rod T
    Value Health; 2013; 16(6):1081-90. PubMed ID: 24041359
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A note regarding meta-analysis of sequential trials with stopping for efficacy.
    Senn S
    Pharm Stat; 2014; 13(6):371-5. PubMed ID: 25296692
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A simple meta-analytic approach for using a binary surrogate endpoint to predict the effect of intervention on true endpoint.
    Baker SG
    Biostatistics; 2006 Jan; 7(1):58-70. PubMed ID: 15972889
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Response to letter to the editor from Dr Rahman Shiri: The challenging topic of suicide across occupational groups.
    Niedhammer I; Milner A; Witt K; Klingelschmidt J; Khireddine-Medouni I; Alexopoulos EC; Toivanen S; Chastang JF; LaMontagne AD
    Scand J Work Environ Health; 2018 Jan; 44(1):108-110. PubMed ID: 29218357
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pitfalls in meta-analyses on adverse events reported from clinical trials.
    Huang HY; Andrews E; Jones J; Skovron ML; Tilson H
    Pharmacoepidemiol Drug Saf; 2011 Oct; 20(10):1014-20. PubMed ID: 21858897
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The safety and effectiveness of different methods of earwax removal: a systematic review and economic evaluation.
    Clegg AJ; Loveman E; Gospodarevskaya E; Harris P; Bird A; Bryant J; Scott DA; Davidson P; Little P; Coppin R
    Health Technol Assess; 2010 Jun; 14(28):1-192. PubMed ID: 20546687
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effectiveness of internet-based e-learning on clinician behavior and patient outcomes: a systematic review protocol.
    Sinclair P; Kable A; Levett-Jones T
    JBI Database System Rev Implement Rep; 2015 Jan; 13(1):52-64. PubMed ID: 26447007
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bias in meta-analysis and funnel plot asymmetry.
    Biljana M; Jelena M; Branislav J; Milorad R
    Stud Health Technol Inform; 1999; 68():323-8. PubMed ID: 10724898
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Detecting outlying trials in network meta-analysis.
    Zhang J; Fu H; Carlin BP
    Stat Med; 2015 Aug; 34(19):2695-707. PubMed ID: 25851533
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Validation of surrogate endpoints in cancer clinical trials via principal stratification with an application to a prostate cancer trial.
    Tanaka S; Matsuyama Y; Ohashi Y
    Stat Med; 2017 Aug; 36(19):2963-2977. PubMed ID: 28485043
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal.
    Hettle R; Corbett M; Hinde S; Hodgson R; Jones-Diette J; Woolacott N; Palmer S
    Health Technol Assess; 2017 Feb; 21(7):1-204. PubMed ID: 28244858
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Deficits and remedy of the standard random effects methods in meta-analysis.
    Ziegler S; Koch A; Victor N
    Methods Inf Med; 2001 May; 40(2):148-55. PubMed ID: 11424301
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.